Open Access to Anti-VEGF Therapies in Retinal Vascular Diseases

This episode, titled “Open Access to Anti-VEGF Therapies in Retinal Vascular Diseases,” features panelists discussing how formulary design, physician choice, and utilization management strategies may influence treatment selection and long-term outcomes in neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The expert faculty explore the balance between maintaining sustainable healthcare spending and preserving clinician flexibility to select the most appropriate anti-VEGF therapy for individual patients.

The panel examines how open access to anti-VEGF therapies may allow retina specialists to make treatment decisions based on disease severity, retinal anatomy, and anticipated treatment response at the point of care. The discussion also addresses how prior authorization requirements and step therapy policies may create delays in treatment initiation, increase administrative burden, and potentially contribute to avoidable vision loss in time-sensitive retinal diseases. In addition, the expert faculty discuss the complexities of balancing cost-effective care with individualized treatment approaches. The panel highlights that while lower-cost therapies may work well for many patients, some individuals may require branded or next-generation anti-VEGF agents to adequately control disease activity and preserve vision.

The discussion emphasizes that physician choice should be paired with responsible treatment selection and evidence-based use of higher-cost therapies when clinically appropriate. Throughout the episode, the expert faculty examine collaboration between payers, physicians, and healthcare systems to create sustainable access strategies that support both cost stewardship and optimal patient outcomes. The panel also highlight the potential value of integrating real-world evidence and clinician input into future formulary and utilization management decisions.

In the next episode, “Role of Prior Authorization in Accessing Anti-VEGF Therapies in Retinal Vascular Diseases,” panelists will examine how utilization management strategies may impact access to anti-VEGF therapies and contribute to administrative burden across healthcare systems. The discussion will also highlight opportunities for more targeted authorization approaches and greater collaboration between payers and retina specialists to improve efficiency and patient care.